Centene posts loss but promises profitability gains in 2026, shares rise

Centene (CNC.N) reported a surprise Q2 adjusted loss of $0.16 per share and sharply lowered its 2025 profit outlook to $1.75, attributing the underperformance to revised ACA risk adjustment payments and a higher-than-expected medical cost ratio of 93% amid rising healthcare expenses. Despite these results, which initially sent shares plummeting, the stock rebounded 5% as the company projected improved profitability in its government-backed insurance businesses by 2026, driven by ongoing repricing efforts for ACA plans.

Analysis

Centene (CNC) presented a starkly negative near-term outlook, reporting a surprise Q2 adjusted loss of $0.16 per share against an expected profit of $0.86, and drastically cutting its 2025 adjusted profit forecast to $1.75 per share from a previous expectation of over $7.25. This underperformance is primarily driven by significant margin pressure, evidenced by a medical cost ratio (MCR) of 93%, well above the 89.3% consensus and the industry's typical 80% target. Management attributes the margin erosion to rising medical costs and a downward revision in expected 2025 ACA risk-adjustment payments, suggesting its member base is healthier than the market average, thus yielding lower reimbursements. Despite the stock's initial 16% premarket drop, it recovered to close up 5%, indicating that investors are focusing on management's forward-looking guidance. The company has committed to improved profitability by 2026, pinning its recovery on a complete repricing of its ACA marketplace plans to better align with current cost trends. However, the CFO acknowledged substantial ongoing risks, including an unfavorable customer mix shift, gaps between Medicaid payment rates and actual care costs, and future regulatory changes.

Key Decisions for Investors

• Investors should re-evaluate valuation models using the new 2025 earnings guidance of $1.75 per share, as historical multiples are no longer applicable following the severe downward revision.
• The investment thesis for Centene now hinges on a successful turnaround in 2026, so investors must weigh significant near-term earnings pressure against management's long-term, but unproven, recovery plan.
• Closely monitor the company's medical cost ratio in subsequent quarters, as a failure to meaningfully reduce the 93% figure would be a primary indicator that the core strategy of repricing ACA plans is not delivering the expected results.
• Given the substantial execution risk outlined by management, it is prudent to monitor for concrete progress on repricing and Medicaid rate negotiations rather than relying solely on forward-looking profitability promises.